Influenza - Coronavirus Combo Vaccine Demonstrated Robust Immune Responses

Maryland-based Novavax, Inc. announced on October 15, 2021, that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a presentation during the World Vaccine Congress Europe 2021. A topic of discussion on October 20, 2021, will be Novavax's COVID-NanoFlu™ combination vaccine.

This combo vaccine combines the company's recombinant nanoparticle protein-based COVID-19 and NanoFlu™ vaccines with Matrix-M™ adjuvant in a single formulation.

In preclinical studies, the COVID-NanoFlu Combination Vaccine demonstrated robust, functional immune responses to each component of the quadrivalent influenza vaccine and the SARS-CoV-2 spike protein, with Matrix-M adjuvant playing a key role.

Separately, NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase 3 clinical trials. 

In September 2021, Novavax announced the publication of complete results from a pivotal Phase 3 clinical trial of NanoFlu in The Lancet Infectious Diseases. In the full analysis, NanoFlu was well-tolerated and produced significantly enhanced humoral and cellular immune responses versus the comparator vaccine.

"Despite high vaccination rates, limitations in the effectiveness of existing influenza vaccines leave significant disease burden unaddressed, particularly in older adults," stated Stanley C. Erck, President, and CEO, Novavax, in a press release issued on September 23, 2021. "These encouraging (study) results reflect NanoFlu's promise, especially as we currently have a combination COVID-19-influenza vaccine under evaluation for protection against two life-threatening diseases simultaneously."

 Novavax, Inc. is a late-stage biotechnology company that promotes improved health globally by discovering, developing, and commercializing innovative vaccines to prevent serious infectious diseases.

Note: The European Medicines Agency started a rolling review of NVX-CoV2373, a COVID‑19 vaccine being developed by Novavax CZ AS (a subsidiary of Novavax, Inc.), in early 2021.